Evidence mapPaperPMID 41515170Full record

ReviewNutrients2025

Influence of Certain Natural Bioactive Compounds on Glycemic Control: A Narrative Review.

Marta Pelczyńska, Starosta Szymon, Michał Konieczny, Hubert Bączyk, Jakub Szyszko, Krzysztof Cholewa, Paweł Bogdański

Abstract readReview
In one paragraph

Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Marta PelczyńskaDepartment of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, 49 Przybyszewskiego Street, 60-355 Poznan, Poland.ORCID 0000-0003-4548-032X
Starosta SzymonFaculty of Medicine, Poznan University of Medical Sciences, 70 Bukowska Street, 60-812 Poznan, Poland.
Michał KoniecznyFaculty of Medicine, Poznan University of Medical Sciences, 70 Bukowska Street, 60-812 Poznan, Poland.
Hubert BączykFaculty of Medicine, Poznan University of Medical Sciences, 70 Bukowska Street, 60-812 Poznan, Poland.
Jakub SzyszkoFaculty of Medicine, Poznan University of Medical Sciences, 70 Bukowska Street, 60-812 Poznan, Poland.
Krzysztof CholewaFaculty of Medicine, Poznan University of Medical Sciences, 70 Bukowska Street, 60-812 Poznan, Poland.
Paweł BogdańskiDepartment of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, 49 Przybyszewskiego Street, 60-355 Poznan, Poland.ORCID 0000-0002-0563-1624

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glycemic control disorders, including insulin resistance (IR) and type 2 diabetes (T2D), represent a major global health challenge. Although existing therapeutic strategies demonstrate effectiveness regarding glycemic control and reduction in diabetes-associated mortality, they are often associated with limited patient tolerance and adherence. Consequently, there is growing interest in natural bioactive compounds that may support glycemic regulation while potentially posing a lower risk of adverse effects in ongoing therapy. The objective of this review is to evaluate the potential of selected natural substances in the context of blood glucose regulation. The analysis encompasses data from in vitro, in vivo, and clinical studies on compounds such as mannoheptulose, β-carotene, resveratrol, steviol glycosides, and curcumin. These agents have demonstrated the ability to modulate key metabolic pathways, enhance tissue insulin sensitivity, reduce oxidative stress, and support pancreatic β-cell function. Particularly promising effects have been observed when some of these compounds are combined with conventional antidiabetic medications, such as metformin. The review also highlights relevant molecular mechanisms, including activation of the AMP-activated protein kinase (AMPK) pathway, increased expression of glucose transporter type 4 (GLUT4), and modulation of gene expression related to insulin sensitivity. Despite encouraging findings, further clinical research is necessary to determine optimal dosages, therapeutic protocols, and the long-term safety of these substances in human populations. Natural bioactive compounds may thus represent a valuable adjunct to current strategies for managing glycemic disorders.

Indexed as

Biological ProductsBlood GlucoseDiabetes Mellitus, Type 2Glycemic ControlHypoglycemic AgentsPhytochemicalsAnimalsbeta CaroteneCurcuminDiterpenes, KauraneGlucosidesHumansInsulin ResistanceOxidative StressResveratrolStilbenesbeta CaroteneBiological ProductsBlood GlucoseCurcuminDiterpenes, KauraneGlucosidesHypoglycemic AgentsPhytochemicalsResveratrolsteviosideStilbenesbioactive compoundscurcuminglycemic controlmannoheptuloseresveratrolsteviosidesβ-carotene

Identifiers

PMID41515170
PMCPMC12788126

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.